-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Inozyme Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2019 to Q1 2025.
- Inozyme Pharma, Inc. Operating Income (Loss) for the quarter ending March 31, 2025 was -$27.7M, a 13.7% decline year-over-year.
- Inozyme Pharma, Inc. Operating Income (Loss) for the twelve months ending March 31, 2025 was -$107M, a 31.6% decline year-over-year.
- Inozyme Pharma, Inc. annual Operating Income (Loss) for 2024 was -$104M, a 37.5% decline from 2023.
- Inozyme Pharma, Inc. annual Operating Income (Loss) for 2023 was -$75.6M, a 10.1% decline from 2022.
- Inozyme Pharma, Inc. annual Operating Income (Loss) for 2022 was -$68.7M, a 21.2% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)